Trident Lifeline Ltd. · BSE:TLL
Trident Lifeline — Q1 FY2025 Earnings Presentation
31 slides from Trident Lifeline's earnings presentation, Jul 20, 2024
Slide 1: BSE filing letter: Earnings Presentation Q1FY25
Date: 20th July, 2024 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, Mumbai – 400001. Sub: Earnings Presentation-Q1FY25. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Ea
Slide 2: Q1FY25 Presentation
Q1FY25 Presentation Tr i d e n t L i f e l i n e L i m i t e d July 2024
Slide 3: Inside the document
Inside the document Pg. 03 __ Company Over view Pg. 09 __ Expansive Product Portfolio Pg. 14 __ Global Footprint Pg. 19 __ Leadership Pg. 21 __ Strategy & Investment Rationale Pg. 24 __ Financials & Management Commentar y
Slide 4: Company Overview
Company Overview
Slide 5: Introduction to Trident Lifeline
Introduction to Trident Lifeline About us A growing force in pharmaceutical Trident Lifeline Limited (“Trident formulations export Vision Lifeline” or “the Company”) 898 1,805 36 To be a leading is a fast-growing pharmaceutical pharmaceutical company Company with business globally by providing high-
Slide 6: Superior Business Model
Superior Business Model A growing force in 898 1,805 36 pharmaceutical Export market Export market product Countries present formulations products registered registrations in process in globally export Asset-light Asset-light State-of-art Strategic M&A third-party contract Contract manufacturing mod
Slide 7: Presence across Value Chain
Presence across Value Chain Procurement Manufacturing Exports Sales & Marketing Complete control over supply- • Third-party contract • Engaged in direct exports • Dedicated sales & marketing chain, procurement done by manufacturing under own brands & product team for branded sales Trident Lifeline i
Slide 8: Strengthening Presence Across Value Chain
Strengthening Presence Across Value Chain Strategic Acquisition of TNS Pharma Private Limited Commissioned Manufacturing Capacity at TNS Tablets: 30 Million Annually 51% Total Equity Stake Acquired April 2024 Commissioned Manufacturing Facility Capsules: Dry Powder Sachin GIDC Classified as a subsid
Slide 9: Strengthening Presence Across Value Chain (continued)
Strengthening Presence Across Value Chain (continued) Strategic Acquisition of Holding stake in TLL Herbal Limited Tricorp Industries Limited 51% Total Equity Stake Acquired 6.21% Total Equity Stake* on 10th August 2023 In the business of herbal In the business of intermediates products. for special
Slide 10: Expansive Product Portfolio
Expansive Product Portfolio
Slide 11: Expansive Product Portfolio
Expansive Product Portfolio The Company’s growing portfolio of products spans over Product categories ▸ Anti Bacterial ▸ Anti Diarrheal ▸ Anti Fungal ▸ Anti Malarial ▸ Anti Diabetic ▸ Dental Cure ▸ Proton Pump Inhibitor ▸ Anti Protozoal Product Categories ▸Anti Histamine 12 ▸Anti Hypertensive drugs
Slide 12: Expansive Product Portfolio (continued)
Expansive Product Portfolio (continued) The Company’s growing portfolio of products spans over Product categories ▸ Capsule ▸ Tablet ▸ Liquid Ointment ▸ Gel ▸ Ice Gel ▸ Mouthwash Product Categories ▸ Paste 12 ▸ Solution ▸ Suspension ▸ Toothpaste Therapeutic Categories 16 ▸ Syrup ▸ Cream 2 PRODUCT PO
Slide 13: Expansive Product Portfolio (continued)
Expansive Product Portfolio (continued) 2,700+ Products in Portfolio 4 PRODUCT PORTFOLIO Trident Lifeline Limited | 12
Slide 14: Revenue Break-up: Product Categories
Expansive Product Portfolio (continued) Revenue Break-up: Product Categories Tablets are by far the largest product category (In %) accounting for 48% of the revenue 0 6 6 7 15 Followed by suspensions being the second largest 21 9 9 23 3 5 category which accounts for 15% of the revenue. 13 4 0 14 Ot
Slide 15: Growing Global Footprint
Growing Global Footprint
Slide 16: Growing Geographical Footprint
Growing Geographical Footprint Trident Lifeline has a growing geographical footprint and a formidable presence export markets such as African, Latin American, CIS and East Asian Uzbekistan countries. Tajikistan 19 Saudi Arabia UAE India Myanmar Panama Sudan Vietnam Philippines Venezuela Cambodia Cou
Slide 17: Geographical Revenue Mix
Geographical Revenue Mix Being an export-oriented The share of exports • Africa is a major export market for the Other key markets for the Company, Trident has been have increased from company Company include constantly growing its export 55% in FY20 to 59% • Followed by increasing share in South •
Slide 18: Bolstering Export Growth
Bolstering Export Growth Trident Lifeline has been making Export product registrations are consistent, upfront investments in a painstaking task, involving export product registrations to significant gestation period bolster revenue growth of 1.5 to 3 years. The Company also needs to register Till d
Slide 19: Bolstering Export Growth (continued)
Bolstering Export Growth (continued) Country-wise product bifurcation Ghana, Venezuela, Cambodia (In %) & Kenya combined accounts for ~60% the total product registered and under registration. TLL has 500+ products registrations filed in Venezuela, followed by Ghana, Cambodia and Kenya. Venezuela 584
Slide 20: Leadership
Q ‘c LY Yo O xe) O O —I
Slide 21: Board of Directors
Board of Directors Mr. Hardik Jigishkumar Desai Mr. Shravan Harikrishna Patel Mrs. Rupaben Chetan Jariwala Mr. Hardik Jigishkumar aged 45 years is Mr. Shravan Harikrishna Patel aged 29 years is Mrs. Rupaben Chetan Jariwala is Whole Time Promoter-Chairman and Executive Director of Managing Director o
Slide 22: Strategy & Investment Rationale
Strategy & Investment Rationale
Slide 23: Strategic Priorities
Strategic Priorities Continuous Expanding investments in intellectual Building sales & Strengthening Expand product product property marketing supply chain portfolio registrations registrations prowess • 300-400 additional • Registering brand’s • Strengthening strategic • Expanding dedicated • Grow
Slide 24: Investment Rationale
Investment Rationale • Trident’s business model reaps • 1,805 registrations in pipeline spread backloaded investment Extensive over 36 countries, with many benefits of product Exponential registrations under advance stages registrations product of the approval growth registrations • Current product
Slide 25: Financials & Management Commentary
Financials & Management Commentary
Slide 26: Quarterly Profit & Loss Snapshot
Quarterly Profit & Loss Snapshot (₹ in Lakh) Particulars Q1FY25 Q4FY24 Q1FY24 YOY Change (%) +59% YOY Revenue growth in Q1FY25 Total Revenue 1,430.45 2,059.46 897.14 59% Total Operating Expenses 1,065.62 1,676.99 687.84 55% EBITDA 364.83 382.47 209.30 74% EBITDA (%) 26% 19% 23% 217 BPS +74% YOY Inte
Slide 27: Management Commentary
Management Commentary • Trident Lifeline starts FY25 on a robust footing. Revenue for Q1FY25 stood at ₹1,430.45 lakh, registering a 59% YOY increase. • Profitability margins remained healthy, with strong operating margins and higher other income contributing to EBITDA growth. • EBITDA for the quarte
Slide 28: Annual Profit & Loss Snapshot
Annual Profit & Loss Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 FY24 Total Revenue 505.63 978.12 2,237.14 3285.02 4670.72 Total Operating Expenses 517.2 836.93 1,905.94 2544.14 3643.79 EBITDA -11.57 141.2 331.2 740.88 1026.93 EBITDA (%) -2% 14% 15% 23% 22% Interest Cost 76.21 41.23 12.58 4
Slide 29: Balance Sheet Snapshot
Balance Sheet Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 FY24 Shareholders Fund -500.31 -217.21 477.57 4710.81 5296.00 Application Money Pending Allotment - - - - 99.00 Non Current Liability 646.93 457.65 148.94 392.83 1287.00 Current Liabilities 286.65 735.61 756.98 1153.40 2025.62 Other
Slide 30: Cash Flow Snapshot
Cash Flow Snapshot (₹ in Lakh) Particulars FY20 FY21 FY22 FY23 FY24 Cash from Operating Activities -81.86 -32.02 -21.47 -1900.43 222.51 Cash from Investing Activities -13.63 24.79 -44.52 -968.71 -2036.38 Cash from Financing Activities 103.75 1.43 80.19 4228.28 1100.82 Net Cash Flow 8.26 -5.8 14.20 1
Slide 31: Safe Harbour
Safe No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of